삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 김지연 교수

진료분야
유방암, 원발부위불명암
진료일정 04 月
날짜
월
01
화
02
수
03
목
04
금
05
토
06
일
07
월
08
화
09
수
10
목
11
금
12
토
13
일
14
월
15
화
16
수
17
목
18
금
19
토
20
일
21
월
22
화
23
수
24
목
25
금
26
토
27
일
28
월
29
화
30
오전
오후
진료일정 05 月
날짜
수
01
목
02
금
03
토
04
일
05
월
06
화
07
수
08
목
09
금
10
토
11
일
12
월
13
화
14
수
15
목
16
금
17
토
18
일
19
월
20
화
21
수
22
목
23
금
24
토
25
일
26
월
27
화
28
수
29
목
30
금
31
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
2020.02 서울대학교 의과대학 의학박사 졸업
2008.02 서울대학교 의과대학 의학학사 졸업
2004.02 KAIST (한국과학기술원) 생명과학부 학사 졸업

경력

경력
2021.03 ~현재 삼성서울병원 혈액종양내과 조교수
2020.03 ~ 2021.02 삼성서울병원 혈액종양내과 진료조교수
2015.03 ~ 2020.02 삼성서울병원 혈액종양내과 임상조교수
2013.03 ~ 2015.02 서울대학교병원 혈액종양내과 임상강사
2009.03 ~ 2013.02 서울대학교병원 내과 전공의 과정 수료
2008.03 ~ 2009.02 서울대학교병원 인턴 과정 수료
논문
  • BREAST CANCER-TOKYO 2024 10.1007/s12282-024-01559-5 Comprehensive Young Age Breast Cancer registry from clinical, genomics, and patient-reported outcomes measured with 15 years follow-up: the CHARM cohort profile Kang, DB; Park, S; Kim, HJ; Lee, JS; Han, JY; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Kim, JY; Nam, SJ; Cho, JH; Park, YH
    View PubMed
  • BREAST CANCER RES 2024 10.1186/s13058-024-01768-y c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer Park, J; Chang, ES; Kim, JY; Chelakkot, C; Sung, M; Song, JY; Jung, K; Lee, JH; Choi, JY; Kim, NY; Lee, H; Kang, MR; Kwon, MJ; Shin, YK; Park, YH; Choi, YL
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.673 Impact of Social Support during Diagnosis and Treatment on Disease Progression in Young Patients with Breast Cancer: A Prospective Cohort Study Kang, D; Park, S; Kim, HJ; Kim, SW; Lee, JE; Yu, J; Lee, SK; Kim, JY; Nam, SJ; Cho, J; Park, YH
    View PubMed
  • EUR J CANCER 2023 10.1016/j.ejca.2023.113386 Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16) Kim, SH; Im, SA; Suh, KJ; Lee, KH; Kim, MH; Sohn, J; Park, YH; Kim, JY; Jeong, JH; Lee, KE; Choi, IS; Park, KH; Kim, HJ; Cho, EK; Park, SY; Kim, M; Kim, JH
    View PubMed
  • ACAD RADIOL 2023 10.1016/j.acra.2023.03.008 Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications Oh, J; Han, BK; Ko, EY; Ko, ES; Choi, JS; Kim, H; Park, YH; Kim, JY
    View PubMed
  • BREAST 2023 10.1016/j.breast.2023.103594 Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/ pertuzumab for HER2-positive breast cancer Kim, N; Kim, JY; Park, W; Cho, WK; Kim, TG; Im, YH; Ahn, JS; Lee, JE; Nam, SJ; Kim, SW; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Park, YH; Kim, H
    View PubMed
  • INT J MOL SCI 2023 10.3390/ijms242115576 A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Jung, HH; Kim, JY; Cho, EY; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • RADIAT ONCOL 2023 10.1186/s13014-023-02357-7 Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach Kim, N; Kim, H; Park, W; Cho, WK; Kim, TG; Im, YH; Ahn, JS; Park, YH; Kim, JY
    View PubMed
  • CANCERS 2023 10.3390/cancers15194720 Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer Shin, J; Kim, JY; Oh, JM; Lee, JE; Kim, SW; Nam, SJ; Park, W; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1565 A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy Won, YW; Kang, JH; Kwon, JH; Koo, DH; Kang, JH; Maeng, CH; Ahn, HK; Oh, SY; Lee, DW; Sohn, J; Oh, SY; Lee, KH; Koh, SJ; Lee, KS; Kim, CK; Kim, JY; Ji, JH; Kim, SB; Ha, JY; Kim, HY
    View PubMed
  • THER ADV MED ONCOL 2023 10.1177/17588359231189421 Pretreatment endocrine symptoms and recurrence-free survival among young premenopausal patients with breast cancer: a prospective cohort study Kang, DB; Cho, JH; Park, S; Kim, HJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Kim, JY; Nam, SJ; Park, YH
    View PubMed
  • EXP MOL MED 2023 10.1038/s12276-023-01030-z Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer Kim, JY; Park, S; Cho, EY; Lee, JE; Jung, HH; Chae, BJ; Kim, SW; Nam, SJ; Cho, SY; Park, YH; Ahn, JS; Lee, S; Im, YH
    View PubMed
  • CANCERS 2023 10.3390/cancers15133435 Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study Kwak, Y; Jang, SY; Choi, JY; Lee, H; Shin, DS; Park, YH; Kim, JY; Ahn, JS; Chae, BJ; Yu, J; Lee, JE; Kim, SW; Nam, SJ; Ryu, JM
    View PubMed
  • GENOME MED 2023 10.1186/s13073-023-01201-7 Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer Park, YH; Im, SA; Park, K; Wen, J; Lee, KH; Choi, YL; Lee, WC; Min, A; Bonato, V; Park, S; Ram, S; Lee, DW; Kim, JY; Lee, SK; Lee, WW; Lee, J; Kim, M; Kim, HS; Weinrich, SL; Ryu, HS; Kim, TY; Dann, S; Kim, YJ; Fernandez, DR; Koh, J; Wang, SG; Park, SY; Deng, SB; Powell, E; Ravi, RK; Bienkowska, J; Rejto, PA; Park, WY; Kan, ZY
    View PubMed
  • CANCERS 2023 10.3390/cancers15133431 Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Kim, JY; Shin, J; Ahn, JS; Park, YH; Im, YH
    View PubMed
  • CANCER MED-US 2023 10.1002/cam4.5953 TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors Kim, JY; Jung, J; Kim, KM; Lee, J; Im, YH
    View PubMed
  • J BREAST CANCER 2023 10.4048/jbc.2023.26.e17 Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level Ryu, JM; Kang, DB; Cho, JH; Lee, JE; Kim, SW; Nam, SJ; Lee, SK; Kim, YJ; Im, YH; Ahn, JS; Park, YH; Kim, JY; Lee, HYJ; Kang, MR; Yu, JH
    View PubMed
  • FRONT ONCOL 2023 10.3389/fonc.2023.1146934 Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer Kim, JY; Kim, J; Cho, EY; Park, YH; Ahn, JS; Kim, KM; Im, YH
    View PubMed
  • J BREAST CANCER 2022 10.4048/jbc.2022.25.e33 Multicentric Breast Cancer of the Axillary and Pectoral Breasts: A Case Report and Literature Review Kim, H; Ko, EY; Han, BK; Kim, JY; Chae, BJ; Lee, H
    View PubMed
  • CANCERS 2022 10.3390/cancers14194839 Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort Jo, H; Park, S; Kim, HR; Kim, H; Hong, J; Lee, JE; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Oh, SY; Choi, SJ; Kim, JY; Ahn, JS; Im, YH; Nam, EM; Nam, SJ; Park, YH
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.1103 Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer Lee, YP; Lee, MS; Kim, H; Kim, JY; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.901 Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/ Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience Kim, JY; Nam, SJ; Lee, JE; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Ahn, JS; Im, YH; Kim, SW; Park, YH
    View PubMed
  • J AM ACAD DERMATOL 2022 10.1016/j.jaad.2021.10.047 Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial Kang, D; Kim, N; Im, YH; Park, YH; Kim, JY; Park, H; Kim, E; Zhao, D; Guallar, E; Ahn, JS; Cho, J
    View PubMed
  • JAMA ONCOL 2022 10.1001/jamaoncol.2022.2310 Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer The Neo-PATH Phase 2 Nonrandomized Clinical Trial Ahn, HK; Sim, SH; Suh, KJ; Kim, MH; Jeong, JH; Kim, JY; Lee, DW; Ahn, JH; Chae, H; Lee, KH; Kim, JH; Lee, KS; Sohn, JH; Choi, YL; Im, SA; Jung, KH; Park, YH
    View PubMed
  • FRONT ONCOL 2022 10.3389/fonc.2022.903372 Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy Kim, JY; Oh, JM; Lee, SK; Yu, J; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Kim, K; Im, YH
    View PubMed
  • CANCER PREV RES 2021 10.1158/1940-6207.CAPR-20-0542 The Relationship Between Breast Density Change During Menopause and the Risk of Breast Cancer in Korean Women Kang, D; Kim, JY; Kim, JY; Mun, HS; Yoon, SJ; Lee, J; Han, G; Im, YH; Shin, SY; Lee, SK; Yu, JH; Lee, KH; Kim, M; Park, D; Choi, YH; Jeong, OS; Lee, JH; Jekal, SY; Choi, JS; Guallar, E; Chang, Y; Ryu, S; Cho, J; Kang, M
    View PubMed
  • CANCERS 2021 10.3390/cancers13225835 Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach Kim, H; Kim, HJ; Kim, H; Kim, HR; Jo, H; Hong, J; Kim, R; Kim, JY; Ahn, JS; Im, YH; Lee, SK; Kim, H; Shin, SY; Park, YH
    View PubMed
  • CANCERS 2021 10.3390/cancers13215260 Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy Jung, HH; Kim, JY; Cho, EY; Oh, JM; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.759150 Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer? Kim, JY; Oh, JM; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • SCI REP-UK 2021 10.1038/s41598-021-98408-8 Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer Joo, S; Ko, ES; Kwon, S; Jeon, E; Jung, H; Kim, JY; Chung, MJ; Im, YH
    View PubMed
  • BREAST CANCER RES TR 2021 10.1007/s10549-021-06309-1 Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea Park, YH; Karantza, V; Calhoun, SR; Park, S; Lee, S; Kim, JY; Yu, JH; Kim, SW; Lee, JE; Nam, SJ; Aktan, G; Marsico, M
    View PubMed
  • ESMO OPEN 2021 10.1016/j.esmoop.2021.100236 Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11) Cho, EH; Kim, JY; Im, SA; Jung, KH; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Jang, JH; Ahn, JH; Park, MS; Lee, SY; Park, YH
    View PubMed
  • CLIN BREAST CANCER 2021 10.1016/j.clbc.2020.12.013 Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype Kim, HK; Lee, HS; Heo, MH; Kim, JY; Ahn, JS; Im, YH; Lee, JI; Park, YH
    View PubMed
  • BREAST CANCER RES TR 2021 10.1007/s10549-021-06310-8 Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer Kim, JY; Jeon, E; Kwon, S; Jung, H; Joo, S; Park, Y; Lee, SK; Lee, JE; Nam, SJ; Cho, EY; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.596364 Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry Kim1, JY; Lee, YS; Yu, J; Park, Y; Lee, SK; Lee, M; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Kang, M; Im, YH
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.653243 The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study Lee1, K; Sim, SH; Kang, EJ; Seo, JH; Chae, H; Lee, KS; Kim, JY; Ahn, JS; Im, YH; Park, S; Park, YH; Park, IH
    View PubMed
  • DIAGNOSTICS 2021 10.3390/diagnostics11020370 Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea Hong1, J; Lee, J; Kwon, M; Kim, JY; Kim, JW; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • NAT COMMUN 2020 10.1038/s41467-020-19933-0 Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome Park1, YH; Lal, S; Lee, JE; Choi, YL; Wen, J; Ram, S; Ding, Y; Lee, SH; Powell, E; Lee, SK; Yu, JH; Ching, KA; Nam, JY; Kim, SW; Nam, SJ; Kim, JY; Cho, SY; Park, S; Kim, J; Hwang, S; Kim, YJ; Bonato, V; Fernandez, D; Deng, S; Wang, S; Shin, H; Kang, ES; Park, WY; Rejto, PA; Bienkowska, J; Kan, Z
    View PubMed
  • ANN TRANSL MED 2020 10.21037/atm-20-3466 Treatment strategy for papillary renal cell carcinoma type 2 a case series of seven patients treated based on next generation sequencing data Kim1, JY; Jeong, HO; Heo, DS; Keam, B; Moon, KC; Kwak, C; Jang, J; Kim, S; Kim, JI; Lee, S; Lee, SH
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-75620-6 The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer Lee1, SY; Kim, EK; Kim, JY; Park, TK; Choi, SH; Im, YH; Kim, MY; Park, YH; Kim, DK
    View PubMed
  • J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199 Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity Hong1, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY
    View PubMed
  • MOL CANCER RES 2020 10.1158/1541-7786.MCR-19-1108 Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer Park1, S; Lee, E; Park, S; Lee, S; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Kim, JY; Ahn, JS; Im, YH; Park, WY; Park, K; Park, YH
    View PubMed
  • BREAST CANCER RES TR 2020 10.1007/s10549-020-05874-1 Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer Kim1, JY; Jung, HH; Sohn, I; Woo, SY; Cho, H; Cho, EY; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • BREAST CANCER RES TR 2020 10.1007/s10549-020-05891-0 Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib Kim1, JY; Park, K; Im, SA; Jung, KH; Sohn, J; Lee, KS; Kim, JH; Yang, Y; Park, YH
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-70584-z Cytokine profiling in serum-derived exosomes isolated by different methods Jung1, HH; Kim, JY; Lim, JE; Im, YH
    View PubMed
  • CANCERS 2020 10.3390/cancers12051306 Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience Hur1, JY; Kim, JY; Ahn, JS; Im, YH; Lee, J; Kwon, M; Park, YH
    View PubMed
  • LANCET ONCOL 2019 10.1016/S1470-2045(19)30565-0 Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial Park1, YH; Kim, TY; Kim, GM; Kang, SY; Park, IH; Kim, JH; Lee, KE; Ahn, HK; Lee, MH; Kim, HJ; Kim, HJ; Lee, JI; Koh, SJ; Kim, JY; Lee, KH; Sohn, J; Kim, SB; Ahn, JS; Im, YH; Jung, KH; Im, SA
    View PubMed
  • BREAST CANCER RES TR 2019 10.1007/s10549-019-05400-y Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11) Kim1, JY; Lee, E; Park, K; Im, SA; Sohn, J; Lee, KS; Chae, YS; Kim, JH; Kim, TY; Jung, KH; Park, YH
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32188 Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients Kim1, JY; Lee, E; Park, K; Jung, HH; Park, WY; Lee, KH; Sohn, J; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Im, SA; Park, YH
    View PubMed
  • KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.226 Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Heo1, MH; Kim, HK; Lee, H; Kim, JY; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • CANCER COMMUN 2019 10.1186/s40880-019-0375-7 Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) Kim1, JY; Park, S; Im, SA; Kim, SB; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH; Park, YH
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.262 Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data Kim1, EK; Cho, J; Kim, JY; Chang, SA; Park, SJ; Choi, JO; Lee, SC; Ahn, JS; Park, SW; Im, YH; Jeon, ES; Park, YF
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.342 Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance Kim1, HK; Park, KH; Kim, Y; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Lee, JE; Ahn, JS; Im, YH; Yu, JH; Park, YH
    View PubMed
  • ONCOL LETT 2019 10.3892/ol.2018.9754 Clinical features and prognosis of breast cancer with gastric metastasis Hong1, J; Kim, Y; Cho, J; Lim, SW; Park, SE; Kim, HK; Lee, H; Cho, SY; Kim, JY; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • BMC CANCER 2019 10.1186/s12885-018-5258-9 Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea Kim1, HK; Lee, SH; Kim, YJ; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Ahn, JS; Im, YH; Yu, JH; Park, YH
    View PubMed
  • EUR J CANCER 2018 10.1016/j.ejca.2018.08.004 Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study) Kim1, JY; Im, SA; Jung, KH; Ro, J; Sohn, J; Kim, JH; Park, YH; Kim, TY; Kim, SB; Lee, KS; Kim, GM; Kim, SH; Kim, S; Ahn, JS; Lee, KH; Ahn, JH; Park, IH; Im, YH
    View PubMed
  • BREAST CANCER RES TR 2018 10.1007/s10549-018-4858-z Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort Kim1, JY; Lim, JE; Jung, HH; Cho, SY; Cho, EY; Lee, SK; Yu, JH; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • CLIN BREAST CANCER 2018 10.1016/j.clbc.2018.04.010 Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment Cho1, WK; Choi, DH; Park, W; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY; Ahn, S
    View PubMed
  • Oncoimmunology 2018 10.1080/2162402X.2018.1466768 Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer Park1, SE; Park, K; Lee, E; Kim, JY; Ahn, JS; Im, YH; Lee, C; Jung, H; Cho, SY; Park, WY; Cristescu, R; Park, YH
    View PubMed
  • NAT COMMUN 2018 10.1038/s41467-018-04129-4 Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures Kan1, ZY; Ding, Y; Kim, J; Jung, HH; Chung, W; Lal, S; Cho, S; Fernandez-Banet, J; Lee, SK; Kim, SW; Lee, JE; Choi, YL; Deng, S; Kim, JY; Ahn, JS; Sha, Y; Mu, XJ; Nam, JY; Im, YH; Lee, S; Park, WY; Nam, SJ; Park, YH
    View PubMed
  • J BREAST CANC 2018 10.4048/jbc.2018.21.1.91 Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy Park1, JH; Lee, SK; Lee, JE; Kim, SW; Nam, SJ; Kim, JY; Ahn, JS; Park, W; Yu, J; Park, YH
    View PubMed
  • TRANSL ONCOL 2018 10.1016/j.tranon.2017.10.002 Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast Kim1, JY; Yu, JH; Nam, SJ; Kim, SW; Lee, SK; Park, WY; Noh, DY; Nam, DH; Park, YH; Han, W; Lee, JE
    View PubMed
  • EUR J CANCER 2017 10.1016/j.ejca.2017.10.002 Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer Park1, YH; Im, SA; Kim, SB; Sohn, JH; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, JY; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH
    View PubMed
  • BREAST 2017 10.1016/j.breast.2017.07.006 Isolated pachymeningeal metastasis from breast cancer: Clinical features and prognostic factors Heo1, MH; Cho, YJ; Kim, HK; Kim, JY; Park, YH
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.21198 Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy Kim1, JY; Park, D; Son, DS; Nam, SJ; Kim, SW; Jung, HH; Kim, YJ; Park, G; Park, WY; Lee, JE; Park, YH
    View PubMed
  • BREAST CANCER RES TR 2017 10.1007/s10549-017-4268-7 A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy Kim1, JY; Ok, ON; Seo, JJ; Lee, SH; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes Kim JY11, Lee E2, Park K2, Park WY2, Jung HH3, Ahn JS1, Im YH1,4, Park YH1,4,3.
    View PubMed
  • Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414. The effect of androgen receptor expression on clinical characterization of metastatic breast cancer Kim JY11, Park K2, Lee E2, Jung HH3, Ahn JS1, Im YH1,4, Park WY2,5, Park YH1,4,3.
    View PubMed
  • Cancer Res Treat. 2016 Oct;48(4):1338-1350. Epub 2016 Feb 18. Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer Kim JY11, Park K2, Jung HH3, Lee E2, Cho EY4, Lee KH5, Bae SY6, Lee SK6, Kim SW6, Lee JE6, Nam SJ6, Ahn JS1, Im YH1,3, Park YH1,3.
    View PubMed
  • Cancer Res Treat. 2016 Oct;48(4):1382-1388. Epub 2016 Mar 11. Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea Kim HK11, Ham JS1, Byeon S1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Lee JY1, Lim SH1, Kim HS1, Kim JY1, Lee JE2, Kim SW2, Nam SJ2, Lee SK2, Bae SY2, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency Jung HH11, Lee SH2, Kim JY2, Ahn JS2, Park YH1,2,3, Im YH2,3.
    View PubMed
  • SCIENTIFIC REPORTS, AUG 22 2016, 6, DOI: 10.1038/srep31804 The relationship between nuclear factor (NF)-kappa B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment Kim JY1, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH
    View PubMed
  • Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623. Gene Expression Profiling of Breast Cancer Brain Metastasis Lee JY11, Park K2, Lee E2, Ahn T2, Jung HH3, Lim SH1, Hong M4, Do IG4, Cho EY4, Kim DH5, Kim JY1, Ahn JS1, Im YH1,2, Park YH1,3.
    View PubMed
  • BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3. Prognostic value of ERBB4 expression in patients with triple negative breast cancer Kim JY11, Jung HH2, Do IG3, Bae S4, Lee SK5, Kim SW6, Lee JE7, Nam SJ8, Ahn JS9, Park YH10,11, Im YH12,13.
    View PubMed
  • Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer Lee JY11, Park K2, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Hong M3, Do IG3, Ahn T2, Lee SK4, Bae SY4, Kim SW4, Lee JE4, Nam SJ4, Kim DH5, Jung HH6, Kim JY1, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer Park YH11,2, Shin HT3, Jung HH2, Choi YL3, Ahn T3, Park K3, Lee A4, Do IG5, Kim JY1,2, Ahn JS1, Park WY3, Im YH1,2.
    View PubMed